Atossa Genetics PE Ratio 2012-2024 | ATOS

Atossa Genetics PE ratio as of September 20, 2024 is 0.00.

Current and historical p/e ratio for Atossa Genetics (ATOS) from 2012 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Atossa Genetics PE Ratio 2012-2024 | ATOS

Current and historical p/e ratio for Atossa Genetics (ATOS) from 2012 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$233.1B
Intuitive Surgical (ISRG)$171.3B
Alcon (ALC)$47.7B
IQVIA Holdings (IQV)$44.2B
IDEXX Laboratories (IDXX)$42.1B
Edwards Lifesciences (EW)$40.7B
DexCom (DXCM)$27.8B
STERIS (STE)$23.5B
SONOVA HOLDING (SONVY)$20.8B
Waters (WAT)$19.8B
Hologic (HOLX)$19B
Sysmex ADR (SSMXY)$12.3B
Fresenius Medical Care AG KGaA (FMS)$12.2B
Teleflex (TFX)$11.4B
Globus Medical (GMED)$9.4B
Penumbra (PEN)$7.6B
Glaukos (GKOS)$6.7B
Masimo (MASI)$6.1B
TransMedics (TMDX)$5.2B
PROCEPT BioRobotics (PRCT)$4.3B
Integer Holdings (ITGR)$4.3B
Tandem Diabetes Care (TNDM)$2.8B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.6B
Inari Medical (NARI)$2.6B
Elekta AB (EKTAY)$2.6B
Nihon Kohden (NHNKY)$2.5B
RxSight (RXST)$2B
Integra LifeSciences Holdings (IART)$1.4B
Pulse Biosciences (PLSE)$1.2B